The main indication for amitriptyline are depressions of varied causes (particularly endogenous forms) that severely jeopardize the well-being of the individual. In the best case scenario 70% of the treated patients respond to amitriptyline. The effect often only sets in after approximately three weeks. Placebo-controlled studies are hardly available. However, amitriptyline has been compared to almost all the new antidepressant agents and usually always showed similar antidepressant effects as comparable substances. It has a strong sedative effect.

The efficiency on chronic pain is also well documented. Amitriptyline acts quickly on pain and its action is unaffected by simultaneous depressive states. It can be used successfully for postherpetic neuralgias and other peripheral neuropathies (e.g. diabetes) and for interval therapy of migraines.

Several authors have also observed a beneficial effect on bulimia. The effect of amitriptyline on anorexia, however, is controversial. The same is true for its use on alcoholism, anxiety syndromes, bedwetting, panic seizures, tension headaches and compulsive syndromes.

Table of Contents | Pharmacology | Adverse Reactions & Interactions | Contraindications & Cautions | Risk Groups | References